Relationship Between Melatonin Receptor Agonists and Parkinson's Disease DOI Creative Commons
Yoshihiro Noguchi,

Rikuto Masuda,

Haruka Aizawa

et al.

Journal of Pineal Research, Journal Year: 2024, Volume and Issue: 76(5)

Published: Aug. 1, 2024

Abstract Parkinson's disease affects millions of people worldwide, and without significant progress in prevention treatment, its incidence prevalence could increase by more than 30% 2030. Researchers have focused on targeting sleep the circadian system as a novel treatment strategy for disease. This study investigated association between melatonin receptor agonists disease, using Food Drug Administration (FDA) Adverse Events Reporting System (FAERS). The target drugs were including ramelteon, tasimelteon, agomelatine. cases defined according to Medical Dictionary Regulatory Activities (MedDRA) 25.0; Standardized MedDRA Query (SMQ) both “narrow” “broad” preferred terms (PTs) associated with (ramelteon, agomelatine) was evaluated reporting odds ratio. Upon analyzing data from all patients registered FAERS, ramelteon (ROR: 0.66, 95% confidence interval [95% CI]: 0.51–0.84) tasimelteon 0.49, CI: 0.38–0.62) showed negative correlations Conversely, only agomelatine positively correlated 2.63, 2.04–3.40). These results suggest that among agonists, are negatively In contrast, shown be should used research develop fully considering limitations spontaneous system.

Language: Английский

Assessment of causality association between serum adiponectin levels and the risk of Alzheimer’s disease and Parkinson’s disease: a Mendelian randomization study DOI Creative Commons

Jiali Lin,

Langhuan Lei,

Qiuyu Liang

et al.

Frontiers in Neurology, Journal Year: 2025, Volume and Issue: 16

Published: April 30, 2025

Background Until recently, the association between circulating adiponectin (ADPN) levels and risk of Alzheimer’s disease (AD) Parkinson’s (PD) remained unclear. Methods We utilized public data from IEU GWAS database to conduct a two-sample bidirectional Mendelian randomization (MR) analysis multiple sensitivity analyses. The MR was performed using aggregated data, with genetic score (GRS) serving as an instrumental variable. Results analyses revealed no significant causal genetically determined ADPN AD (OR IVW = 0.852, 95% confidence interval [CI]: 0.586–1.117, p 0.235) or PD 0.830, CI: 0.780–1.156, 0.606). Conversely, neither nor demonstrated any levels. GRS approach yielded similar results ( > 0.05). However, it exhibited negative correlation interleukin 1β (IL1β, β −0.31; −0.55 −0.07, 0.011). Cochrane’s Q test MR-PRESSO evidence pleiotropy. Conclusion Our findings provide substantiate relationship vice versa. elevated may correlate lower IL1β.

Language: Английский

Citations

0
The Therapeutic Potential of Melatonin and Its Novel Synthetic Analogs in Circadian Rhythm Sleep Disorders, Inflammation‐Associated Pathologies, and Neurodegenerative Diseases DOI
Rodrigo F. N. Ribeiro, Maria Rita de Morais Chaves Santos, Maria Aquino

et al.

Medicinal Research Reviews, Journal Year: 2025, Volume and Issue: unknown

Published: May 8, 2025

ABSTRACT Melatonin, N ‐acetyl‐5‐methoxytryptamine, is a tryptophan‐derived hormone mostly produced in the pineal gland, despite being synthesized locally at several tissues and organs. This production rhythmically controlled by complex clock gene networks master pacemaker located suprachiasmatic nucleus of hypothalamus. Melatonin usually secreted only during dark phase day essential to synchronize circadian rhythms neuroendocrine physiological processes. Its main clinical use associated with treatment jet lag other rhythm sleep disorders, growing number promising therapeutic applications due diverse roles melatonin. In this review, we explore melatonin its receptors provide an updated overview on research concerning role melatonin, either as endogenous molecule or drug, in: sleep–wake cycle regulation; rhythms; inflammatory processes that may compromise cardiovascular, respiratory, gastrointestinal, renal, reproductive system functions; neurodegenerative disorders such Alzheimer's Parkinson's disease. The most recent findings synthetic analogs agomelatine ramelteon are highlighted, pointing toward new compounds pharmacological activity while emphasizing their structural differences advantages when compared

Language: Английский

Citations

0
Neuroprotective Potential of Melatonin: Evaluating Therapeutic Efficacy in Alzheimer's and Parkinson's Diseases DOI Open Access
Norris C Talbot,

Patrick M. Luther,

Noah J Spillers

et al.

Cureus, Journal Year: 2023, Volume and Issue: unknown

Published: Dec. 22, 2023

Decreased melatonin levels have been linked to both Alzheimer's disease (AD) and Parkinson's (PD), which are the two most prevalent neurodegenerative disorders. The development of sleep disorders is widespread in patients diagnosed with AD or PD. In this regard, calcification pineal gland, typically seen third decade, has associated a reduction production. Recent studies suggested that exogenous application can be utilized treat diseases. Furthermore, research shown deficiencies PD begin before diagnosis either made. These findings could encourage further on as potential biomarker for possible area early treatment these Many clinical also produced data denoting method reduce detrimental neurocognitive effects Further role diseases expand symptomatic prophylactic options such This review investigates melatonin's physiological properties, its PD, current therapeutic benefits patients.

Language: Английский

Citations

9
Relationship Between Melatonin Receptor Agonists and Parkinson's Disease DOI Creative Commons
Yoshihiro Noguchi,

Rikuto Masuda,

Haruka Aizawa

et al.

Journal of Pineal Research, Journal Year: 2024, Volume and Issue: 76(5)

Published: Aug. 1, 2024

Abstract Parkinson's disease affects millions of people worldwide, and without significant progress in prevention treatment, its incidence prevalence could increase by more than 30% 2030. Researchers have focused on targeting sleep the circadian system as a novel treatment strategy for disease. This study investigated association between melatonin receptor agonists disease, using Food Drug Administration (FDA) Adverse Events Reporting System (FAERS). The target drugs were including ramelteon, tasimelteon, agomelatine. cases defined according to Medical Dictionary Regulatory Activities (MedDRA) 25.0; Standardized MedDRA Query (SMQ) both “narrow” “broad” preferred terms (PTs) associated with (ramelteon, agomelatine) was evaluated reporting odds ratio. Upon analyzing data from all patients registered FAERS, ramelteon (ROR: 0.66, 95% confidence interval [95% CI]: 0.51–0.84) tasimelteon 0.49, CI: 0.38–0.62) showed negative correlations Conversely, only agomelatine positively correlated 2.63, 2.04–3.40). These results suggest that among agonists, are negatively In contrast, shown be should used research develop fully considering limitations spontaneous system.

Language: Английский

Citations

1